Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled multiple-dose study of anrukinzumab in active ulcerative colitis
2010-023762-49Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Anrukinzumab escalating IV doses with Placebo (2 arms). Primary endpoint: Change in fecal calprotectin vs baseline at week 14. Started Feb 2011; status: completed.
02
Drugs
anrukinzumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2010-023762-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023762-49.